35 results about "Red blood cell agglutination" patented technology

The invention relates to the field of biological detection instruments, in particular to a biosensor. The biosensor comprises a reagent layer. The reagent layer contains red blood cell agglutinant or an omentum layer adhering to the reagent layer. The omentum layer is treated through the red blood cell agglutinant. The invention further provides a preparation method and application of the biosensor. As the problem of the sensibility of the hematocrit value is not solved completely in the prior art, the problem of the sensibility of the hematocrit value is solved by reducing the sensibility of the hematocrit value; accordingly, the accuracy of testing results is improved, and interference of red blood cells on the testing results is reduced to the maximum extent.

The invention relates to the technical field of antibody drugs, in particular to an anti-CD47 antibody or an antigen binding fragment thereof, a pharmaceutical composition containing the anti-CD47 antibody or the antigen binding fragment thereof and their application. The anti-CD47 antibody or the antigen binding fragment thereof provided by the invention has significant antitumor activity, has high affinity with the human CD47 protein, can block the ability of SIRPa binding to CD47 on the cell surface, does not have significant erythrocyte agglutination activity, and can be applied to preparation of antitumor drugs.

The invention discloses mesoporous bioactive glass / chitosan composite hemostatic sponge and a preparation method thereof. The method comprises the following steps of preparing mesoporous bioactive glass by using a bicontinuous microemulsion technology in combination with a sol-gel template method, blending a chitosan solution, a polyvinyl alcohol solution and the mesoporous bioactive glass, performing uniform dispersing, adding a cross-linking agent for a reaction, pouring a reaction product into a mold, performing pre-freezing and molding, and performing freeze-drying to obtain the mesoporous bioactive glass / chitosan composite hemostatic sponge. The composite sponge is simple in preparation process; red blood cells are agglutinated through the combination of polycations of a chitosan material and anions on the surface of a blood red cell membrane, platelet aggregation is activated, and thrombin is activated; the mechanical strength, porosity and water absorption rate of the sponge are improved due to the addition of the mesoporous bioactive glass; when being in contact with a wound, the sponge can rapidly absorb liquid, so that the aggregation of platelets and red blood cells is accelerated, blood clots are rapidly formed and accumulated in a sponge network structure with hierarchical pores, and finally the hemostatic effect is achieved; and the sponge has a good application prospect in the field of hemostatic materials.

The invention discloses a kit for ABO blood type positive typing and Rh blood type detection as well as a preparation method and a detection method of the kit. The kit comprises a clamping shell whichis wrapped around an outer part, a detection film, a water absorption pad and a back lining that are located in the clamping shell and sequentially arranged from top to bottom. The detection film iscomposed of a character area and a non-character area, and the character area is composed of letters and symbols; the letters comprise letters A, B, O and letters at an Rh position; the letters at theRh position are one or more combinations of C, c, D, E and e; the symbols comprise a minus sign in the middle of the letter O and an plus sign on the upper right side of the letter Rh; each character comprises a hydrophilic area and a hydrophobic area, and the hydrophilic area is a reaction area. According to an immunofiltration principle, red blood cell agglutination is generated by utilizing specific reaction of red blood cell antigens and antibodies, whether red blood cell agglutination colors exist or not is observed, and a text consisting of colors is interpreted to realize blood type detection. The method is easy to operate, a detection result can be visually judged, and blood transfusion accidents caused by misjudgment are prevented.

Provided are: a method for agglutinating erythrocytes and a method for separating erythrocytes, wherein erythrocytes can be instantaneously agglutinated into a sufficient size from a blood sample, andthe erythrocytes can be completely separated from the blood sample; and a hemagglutination reagent. The method for agglutinating erythrocytes comprises adding a solution, containing a cholic acid-based surfactant and an acid, to a blood sample. The method for separating erythrocytes comprises separating the erythrocytes agglutinated by the method for agglutinating erythrocytes. In addition, the hemagglutination reagent contains a cholic acid-based surfactant and an acid.

The invention relates to an influenza virus attenuating method, an influenza attenuated virus strain and application, and belongs to the technical field of biological medicine. The attenuating method comprises the following steps: carrying out random number and position base deletion on a transmembrane structural domain and a cytoplasm structural domain of M2 protein in an influenza virus conserved region, so as to obtain the influenza attenuated virus with corresponding base deletion. The influenza attenuated virus strain obtained by the attenuating method disclosed by the invention has a good growth characteristic on an MDCK cell line for expressing M2 protein; a high dose of virus strain can grow in MDCK cells or chick embryos and has a high chicken red blood cell agglutination price; in addition, a Balb / C mouse is immunized through nasal dripping, and it is found that the virus strain is non-pathogenic to the mouse relative to the parent virus IAV PR8. The virulence of the influenza virus is reduced in a random base deletion mode, and a foundation is laid for screening of safer and more effective IAV attenuated live vaccines.

The invention belongs to the technical field of image processing, and discloses a blood type card image feature extraction method, which comprises the following steps: acquiring a microcolumn tubule image; separating the microcolumn tubule image into a red channel image, a green channel image and a blue channel image, merging color channels, and extracting a color region reflecting red blood cells; and counting the total expected value of the gray values by adopting an information entropy method, and distinguishing erythrocyte agglutination or dissociation by counting the total expected value of the gray values. Color features and gray features are comprehensively extracted, a novel feature extraction algorithm is provided, and the image analysis efficiency and interpretation accuracy of a blood type interpretation system are greatly improved.

The invention discloses a sargassum thunbergii lectin and a preparation method thereof, wherein the preparation method of the sargassum thunbergii lectin is characterized by selecting sargassum thunbergii as a raw material, carrying out lyophilization, pulverization, immersion, centrifugation, ammonium sulfate fractionation, DEAE-52 ion-exchange chromatography and SephadexG-200 gel filtration chromatography, thus producing the sargassum thunbergii lectin with a molecular weight of 17 kD. The sargassum thunbergii lectin of the invention can agglutinate a wide range of cells, has agglutinative functions for erythrocytes of rabbits, dogs, sheep, crucians, chickens and humans (A, B, AB), and the like, wherein minimum concentrations of agglutination reactions with rabbit and chicken erythrocytes are 4.4mg / ml and 0.55 mg / ml respectively, and shows hemagglutinin activity for rabbit erythrocytes even after heating treatment at 100 DEG C for 30 min (the activity decreases by 75%). A sugar inhibition experiment shows that the sargassum thunbergii lectin is only inhibited by glycoproteins as bovine thyroglobulin and gamma-globulin, and the minimum inhibition concentrations are 1.25 mg.mL<-1> and 2.5 mg.mL<-1> respectively.

The invention discloses a hybridoma cell strain 105D11 and an anti-human CD47 monoclonal antibody generated from the hybridoma cell strain 105D11. A high-affinity anti-human CD47 specific monoclonal antibody which can block the interaction of CD47-SIRPalpha is prepared by using CD47 recombinant protein with bioactivity as an antigen through screening of a hybridoma technique. Meanwhile, an in-vitro experiment proves that the anti-human CD47 specific monoclonal antibody generated from the hybridoma cell strain 105D11 can promote macrophages to phagocytize tumor cells and cannot cause agglutination of erythrocytes. Therefore, the antibody has a potential value in tumor immunotherapy.

The invention relates to active polypeptide and a gene thereof, and application of the active polypeptide to pharmacy. Microhyla pulchra antioxidation peptide is cyclopeptide consisting of 12 pieces of amino acid, wherein the molecular weight is 1334.91 daltons; the isoelectric point is 8.002; the amino acid sequence is SEQ ID NO.1; and the third-position cysteine and the eleventh-position cysteine of the polypeptide form intramolecular disulfide bonds. The gene sequence of the microhyla pulchra antioxidation peptide consists of SEQ ID NO.4, and the gene encoded with the functional mature microhyla pulchra antioxidation peptide is the 187th to the 222nd position nucleotide. The gene of the microhyla pulchra antioxidation peptide deduces the mature functional polypeptide amino acid sequence, and the synthesized microhyla pulchra antioxidation peptide has strong erythrocyte agglutination and anti-oxidation functions.

The invention relates to a colloidal gold detection card for rapidly detecting rabbit plague virus and a preparation method thereof. The specific steps are: (1) preparation of paired anti-rabbit plague virus monoclonal antibodies, including immune procedures, cell fusion, hybridoma screening and Cloning, antibody preparation and purification; (2) colloidal gold detection card for rapid detection of rabbit plague virus and its preparation method, including preparation of colloidal gold monoclonal antibody, sample pad treatment, spray film, C and T line determination, tested Sample processing, performance measurement. The invention can quickly, sensitively and accurately detect rabbit plague virus infection in the liver and kidney of rabbits, overcomes the domestic method of detecting rabbit plague virus mainly by red blood cell agglutination test, greatly shortens the detection time, and provides convenience for on-site detection.

The invention discloses a 3F3Rmg recombinant fusion protein and a preparation method thereof. The recombinant fusion protein is encoded by a 3F3Rmg fusion gene obtained by splicing a 3F3ScFv gene and an Rmg gene, and has a base sequence shown in a sequence table SEQ.ID.No.1. Due to the difunctional characteristic of the 3F3Rmg recombinant fusion protein, the fusion protein can be combined with a human red blood cell without being agglutinated, can react with a rabies G antibody, and undergoes an agglutination phenomenon which can be observed by naked eyes under an antibody bridging action. A dog rabies antibody red cell agglutination test diagnostic reagent kit prepared by applying the recombinant fusion protein is easy to operate, has high sensitivity and high specificity, is particularly suitable for detecting the dog rabies antibody, and meets the requirements of use rapidness, easiness and convenience for a substrate field.

The invention relates to a positive serum national standard substance used for a newcastle disease hemagglutination inhibition test and a preparation method thereof. In the positive serum national standard substance used for the newcastle disease hemagglutination inhibition test, Newcastle Disease Virus (NDV) La Sota strain virus and inactivated vaccine immune SPF (Specific Pathoge Free) chicken are utilized to prepare hyperimmune serum to be used as a candidate, through the processes of candidate detection, standard substance preparation, detection, split charging, freeze-drying and the like, the positive serum international standard substance used for the newcastle disease hemagglutination inhibition test obtained by NIBSC (National Institute for Biological Standards and Control) is taken as a reference to carry out a red blood cell agglutination inhibition test to determinate a valence of the standard substance, and through a uniformity test, a stability test, cooperation calibration and data statistics, a constant valence value is ensured to be accurate, and the positive serum national standard substance used for the newcastle disease hemagglutination inhibition test is prepared. The method disclosed by the invention makes the standard substance preparation more scientific, rigorous and perfect according to the standard substance preparation process.

The invention discloses a mesoporous bioactive glass / chitosan composite hemostatic sponge and a preparation method thereof. The method comprises: using double continuous microemulsion technology combined with sol-gel template method to prepare mesoporous bioactive glass, blending chitosan solution, polyvinyl alcohol solution, and mesoporous bioactive glass, and adding a crosslinking agent after uniform dispersion The reaction is poured into a mold, pre-frozen and shaped, and then freeze-dried. The preparation process of the composite sponge is simple, and the combination of the polycation of the chitosan material and the anion on the surface of the red blood cell membrane causes red blood cells to agglutinate, activates platelet aggregation, and activates thrombin at the same time, and the mechanical strength of the sponge is improved due to the addition of mesoporous bioactive glass , porosity and water absorption rate, it can quickly absorb liquid when it contacts the wound, and then accelerate the aggregation of platelets and red blood cells, quickly form blood clots and accumulate in the sponge network structure with multi-level pores, and finally play a hemostatic effect. The field of materials has good application prospects.

The invention discloses a hybridoma cell strain 105D11 and an anti-human CD47 monoclonal antibody generated from the hybridoma cell strain 105D11. A high-affinity anti-human CD47 specific monoclonal antibody which can block the interaction of CD47-SIRPalpha is prepared by using CD47 recombinant protein with bioactivity as an antigen through screening of a hybridoma technique. Meanwhile, an in-vitro experiment proves that the anti-human CD47 specific monoclonal antibody generated from the hybridoma cell strain 105D11 can promote macrophages to phagocytize tumor cells and cannot cause agglutination of erythrocytes. Therefore, the antibody has a potential value in tumor immunotherapy.